Shorted
Chimeric Therapeutics logo
CHM
Pharmaceuticals, Biotechnology & Life Sciences

Chimeric Therapeutics

Short interest
0.00%
−0.13 pp 30d
as of 11 May 2026
Reported shorts
1
Shares on issue
51.822M

Chimeric Therapeutics (CHM) company profile

Profile, insiders and operations

Company

AI-generated research profile of Chimeric Therapeutics

cell therapy
cancer
biotechnology
pharmaceuticals
clinical stage

Chimeric Therapeutics is an Australian clinical-stage cell therapy company focused on developing and commercializing innovative cell therapies for cancer patients. Their diversified portfolio includes autologous CAR T-cell therapies and allogeneic NK cell therapies, targeting multiple oncology disease areas. The company currently has several clinical trials underway.

Director trades

18 trades recorded

DateDirectorTypeSharesPriceValue
2025-12-19Miles Prince
other
16,667,000--
2025-12-19Unknown Director
buy
---
2025-08-21Unknown Director
buy
---
2025-08-19Miles Prince
buy
4,273,142$0.004$14,956
2025-07-01Unknown Director
buy
---
2025-06-26Lesley Russell
other
2,750,000--
2025-05-01Unknown Director
buy
---
2025-05-01Unknown Director
buy
---
2025-04-30Paul Hopper
other
20,000,000$0.003$50,000
2025-04-30Phillip Hains
buy
5,217,392$0.003$13,043.48
2024-12-13Unknown Director
buy
---
2024-12-09Paul Hopper
other
211,580,882$0.004$800,000
2024-04-08Unknown Director
buy
---
2024-04-08Unknown Director
buy
---
2024-03-31Mr Phillip Hains
exercise options
---
2024-03-31Paul Hopper
exercise options
---
2024-02-15Unknown Director
buy
---
2023-12-14Eric Sullivan
exercise options
5,500,000--

CHM intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required